Privia Health Group Inc (PRVA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Privia Health Group Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 23.70 $ — 52% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 16.1% passed
- More than 10% revenue growth is expected for the coming year 9.9% failed
- Share count grows by less than 3% a year 5.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 29.9% failed
- Gross margin at 40% or higher and without meaningful erosion 9.9% failed
- Goodwill from acquisitions does not grow faster than revenue 15.3% failed
- Net debt below twice EBITDA 470 m net cash passed
- Operating cash flow covers the profits of the last three years 293 m passed
- Return on capital at 15% or higher, or up versus two years ago 4.3% passed
- Insiders hold at least 10% or are net buyers 6.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 34.6% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 21
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.95 | 0.74 – 1.20 | 2,424 | -3.9% | 11 |
| 12/31/2027 | 1.10 | 0.73 – 1.41 | 2,665 | 15.4% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.08 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.03 | 53.10 | 461 | 4.60 | 1.00 | 75 | 75 |
| 2025: Q1 | 0.03 | 38.40 | 480 | 15.60 | 0.90 | -24 | -24 |
| 2025: Q2 | 0.02 | -24.40 | 521 | 23.40 | 0.50 | 8 | 8 |
| 2025: Q3 | 0.05 | 89.50 | 580 | 32.50 | 1.20 | 52 | 51 |
| 2025: Q4 | 0.07 | 101.70 | 541 | 17.40 | 1.70 | 128 | 128 |
| 2026: Q1 | 0.02 | -29.10 | 604 | 25.80 | 0.50 | -50 | -50 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 658 | 2 | -3 | -0.03 | 5 | 89 | 249 |
| 2019 | 786 | 16 | 8 | 0.08 | 24 | 110 | 270 |
| 2020 | 817 | 25 | 31 | 0.30 | 39 | 147 | 329 |
| 2021 | 966 | -217 | -188 | -1.75 | 55 | 427 | 686 |
| 2022 | 1,357 | -19 | -9 | -0.08 | 47 | 499 | 793 |
| 2023 | 1,658 | 21 | 23 | 0.19 | 81 | 561 | 1,000 |
| 2024 | 1,736 | 17 | 14 | 0.11 | 109 | 635 | 1,136 |
| 2025 | 2,123 | 34 | 23 | 0.18 | 163 | 737 | 1,369 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Privia Health Group, Inc. ist als landesweites Physician-Enablement-Unternehmen in den USA tätig.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 1,226 |
| Headquarters | Arlington, VA |
| Address | 950 North Glebe Road, 22203 Arlington, United States |
| Phone | 571 366 8850 |
| Website | priviahealth.com |
| IPO Date | 28. Apr 2021 |
| ISIN | US74276R1023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Parth Mehrotra | CEO & Director | 1979 |
| David Mountcastle CPA, MBA | Executive VP & CFO | 1970 |
| Edward Christopher Fargis Esq. | Executive VP, General Counsel, Chief Legal Officer & Corporate Secretary | 1965 |
| Sarath Degala | Chief Operating Officer | – |
| Konda Mullapudi | Executive VP & CTO | – |
| Robert P. Borchert | Senior Vice President of Investor Relations & Corporate Communications | – |
| Dana Fields CPA | Chief Audit & Compliance Officer | – |
| Jenny Harding | Chief People Officer | – |
| Jay Stevens | Senior VP & Chief Growth Officer | – |
| Eric J. Beyer | Executive Vice President of Medical Groups | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 9. Jul 2026 | Mountcastle David | EVP & Chief Financial Officer | Sell | 21,275 | 27.67 | 588,679 |
| 7. Jul 2026 | Mountcastle David | EVP & Chief Financial Officer | Sell | 600 | 27.57 | 16,542 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.